BWH-Led Team Uses 454 GS 20 to Sequence Lung Cancer Transcriptomes | GenomeWeb
A public-private research team led by doctors at Brigham and Women’s Hospital in Boston has used 454’s GS 20 platform to sequence and analyze the transcriptomes of lung tumors, according to a recent study.
 
The team, which included scientists from 454 Life Sciences, the National Center for Genome Resources, and a company called RxGen, sequenced cDNA from four samples of malignant pleural mesothelioma, or MPM, and two controls.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.